Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,523 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Novel Pyrazole-Based Selective Aldosterone Synthase (CYP11B2) Inhibitors: A New Template to Coordinate the Heme-Iron Motif of CYP11B2.
Sakakibara R, Sasaki W, Onda Y, Yamaguchi M, Ushirogochi H, Hiraga Y, Sato K, Nishio M, Egi Y, Takedomi K, Shimizu H, Ohbora T, Akahoshi F. Sakakibara R, et al. Among authors: nishio m. J Med Chem. 2018 Jul 12;61(13):5594-5608. doi: 10.1021/acs.jmedchem.8b00328. Epub 2018 Jun 22. J Med Chem. 2018. PMID: 29878770
Discovery of SPH3127: A Novel, Highly Potent, and Orally Active Direct Renin Inhibitor.
Iijima D, Sugama H, Takahashi Y, Hirai M, Togashi Y, Xie J, Shen J, Ke Y, Akatsuka H, Kawaguchi T, Takedomi K, Kashima A, Nishio M, Inui Y, Yoneda H, Xia G, Iijima T. Iijima D, et al. Among authors: nishio m. J Med Chem. 2022 Aug 25;65(16):10882-10897. doi: 10.1021/acs.jmedchem.2c00834. Epub 2022 Aug 8. J Med Chem. 2022. PMID: 35939295
Discovery of Novel 2-Carbamoyl Morpholine Derivatives as Highly Potent and Orally Active Direct Renin Inhibitors.
Iijima D, Sugama H, Awai N, Takahashi Y, Togashi Y, Takebe T, Xie J, Shen J, Ke Y, Akatsuka H, Kawaguchi T, Takedomi K, Kashima A, Nishio M, Inui Y, Yoneda H, Xia G, Iijima T. Iijima D, et al. Among authors: nishio m. ACS Med Chem Lett. 2022 Aug 1;13(8):1351-1357. doi: 10.1021/acsmedchemlett.2c00280. eCollection 2022 Aug 11. ACS Med Chem Lett. 2022. PMID: 35978678 Free PMC article.
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer.
Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Häfliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ. Skoulidis F, et al. Among authors: nishio m. Oncologist. 2025 Jan 17;30(1):oyae356. doi: 10.1093/oncolo/oyae356. Oncologist. 2025. PMID: 39846981
Role and prognostic value of growth differentiation factor 15 in patient of heart failure with preserved ejection fraction: insights from the PURSUIT-HFpEF registry.
Sakamoto D, Matsuoka Y, Nakatani D, Okada K, Sunaga A, Kida H, Sato T, Kitamura T, Tamaki S, Seo M, Yano M, Hayashi T, Nakagawa A, Nakagawa Y, Yasumura Y, Yamada T, Hikoso S, Sotomi Y, Sakata Y; OCVC-Heart Failure Investigators. Sakamoto D, et al. Open Heart. 2025 Jan 19;12(1):e003008. doi: 10.1136/openhrt-2024-003008. Open Heart. 2025. PMID: 39832941 Free article.
1,523 results